key: cord-0705389-g8vsx1bh
authors: Luo, Lili; Luo, Ting; Du, Mengyi; Mei, Heng; Hu, Yu
title: Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis
date: 2021-11-20
journal: J Infect
DOI: 10.1016/j.jinf.2021.11.013
sha: 0fccbd89989658e4d11a13b8c6e8c952f1ce8437
doc_id: 705389
cord_uid: g8vsx1bh

nan

Lili Luo 1* , Ting Luo 2* , Mengyi Du 1 Figure   1A ). Additionally, TCZ administration in 9 RCTs instigated improved overall mortality (RR=0.91 [0.84-0.98]; P=0.01; I 2 =0%) ( Figure 1B) . However, the largest RCT (RECOVERY NCT04381936)(5) greatly interfered with the pooled result on short-term and overall mortality, possibly because its sample size was much larger than those of other RCTs. Analyses of the 42 cohorts yielded consistent results that TCZ significantly reduced the short-term and overall mortality (Figure 2A and 2B) . 

Interleukin-6 in Covid-19: A systematic review and meta-analysis

Tocilizumab for severe COVID-19: a systematic review and meta-analysis

IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)

Pubmed Central PMCID: PMC8127467 Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals. Advisor: Antegene Biotech LLC, Medical Director: FFF Enterprises Inc. Partner: AZACA Inc. Board of Directors: RakFond Foundation for Cancer Research Support. Scientific Advisory Board

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic Review and meta-analysis: first update

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm